Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hulin Jin

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Oncoimmunology|September 6, 2021
Avelumab internalization by human circulating immune cells is mediated by both Fc gamma receptor and PD-L1 bindingHulin Jin, Vittorio D'Urso, Berend Neuteboom, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 3, 2009
Cutting edge: IL-27 induces the transcription factor c-Maf, cytokine IL-21, and the costimulatory receptor ICOS that coordinately act together to promote differentiation of IL-10-producing Tr1 cellsCaroline Pot, Hulin Jin, Amit Awasthi, et al.
Investigational New Drugs|February 12, 2022
Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumorsSaiama N Waqar, Clifford Robinson, Anthony J Olszanski, et al.
Investigational New Drugs|February 28, 2022
Author Correction: Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumorsSaiama N Waqar, Clifford Robinson, Anthony J Olszanski, et al.
Therapeutic Advances in Neurological Disorders|August 4, 2025
Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS StudyKlaus Schmierer, Heinz Wiendl, Frederik Barkhof, et al.
Frontiers in Immunology|March 20, 2025
Corrigendum: Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS studyHeinz Wiendl, Frederik Barkhof, Xavier Montalban, et al.
Neurology and Therapy|July 4, 2025
Summary of Research: Blood Biomarker Dynamics in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Results of the 2-Year MAGNIFY-MS StudyHeinz Wiendl, Frederik Barkhof, Xavier Montalban, et al.
Frontiers in Immunology|February 18, 2025
Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS studyHeinz Wiendl, Frederik Barkhof, Xavier Montalban, et al.
Neurodegenerative Disease Management|April 7, 2026
A plain language summary on clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS studyKlaus Schmierer, Heinz Wiendl, Frederik Barkhof, et al.
Cancer Research|February 7, 2007
Prevention of mantle lymphoma tumor establishment by routing transferrin receptor toward lysosomal compartmentsYves Lepelletier, Valérie Camara-Clayette, Hulin Jin, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Oncoimmunology|September 6, 2021
Avelumab internalization by human circulating immune cells is mediated by both Fc gamma receptor and PD-L1 bindingHulin Jin, Vittorio D'Urso, Berend Neuteboom, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 3, 2009
Cutting edge: IL-27 induces the transcription factor c-Maf, cytokine IL-21, and the costimulatory receptor ICOS that coordinately act together to promote differentiation of IL-10-producing Tr1 cellsCaroline Pot, Hulin Jin, Amit Awasthi, et al.
Investigational New Drugs|February 12, 2022
Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumorsSaiama N Waqar, Clifford Robinson, Anthony J Olszanski, et al.
Investigational New Drugs|February 28, 2022
Author Correction: Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumorsSaiama N Waqar, Clifford Robinson, Anthony J Olszanski, et al.
Therapeutic Advances in Neurological Disorders|August 4, 2025
Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS StudyKlaus Schmierer, Heinz Wiendl, Frederik Barkhof, et al.
Frontiers in Immunology|March 20, 2025
Corrigendum: Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS studyHeinz Wiendl, Frederik Barkhof, Xavier Montalban, et al.
Neurology and Therapy|July 4, 2025
Summary of Research: Blood Biomarker Dynamics in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Results of the 2-Year MAGNIFY-MS StudyHeinz Wiendl, Frederik Barkhof, Xavier Montalban, et al.
Frontiers in Immunology|February 18, 2025
Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS studyHeinz Wiendl, Frederik Barkhof, Xavier Montalban, et al.
Neurodegenerative Disease Management|April 7, 2026
A plain language summary on clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS studyKlaus Schmierer, Heinz Wiendl, Frederik Barkhof, et al.
Cancer Research|February 7, 2007
Prevention of mantle lymphoma tumor establishment by routing transferrin receptor toward lysosomal compartmentsYves Lepelletier, Valérie Camara-Clayette, Hulin Jin, et al.
Pageof 3